BDBM375623 US9908897, Example 1::US9908897, Example 2

SMILES Fc1cccc(Oc2cc(F)c(F)cc2N2CCC3(CC2)CNCCO3)c1

InChI Key InChIKey=GQORDSCTOHJVGL-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 375623   

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 11nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 2.04E+3nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 363nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 1.00E+3nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 7.24nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 933nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375623(US9908897, Example 1 | US9908897, Example 2)
Affinity DataIC50: 324nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent